IXICO plc Conference attendance - On Helix Digital
08 Julio 2020 - 1:00AM
RNS Non-Regulatory
TIDMIXI
IXICO plc
08 July 2020
IXICO plc
("IXICO" or the "Company")
Conference attendance
On Helix Digital 13-14 July 2020
IXICO plc (AIM: IXI), the data analytics company delivering
insights in neuroscience, announces the Company's digital
attendance at the On Helix Digital conference, on the 13-14 July
2020.
On Helix is a conference organised by One Nucleus, a
non-for-profit Life Sciences & Healthcare organisation
supporting institutions, companies and individuals working in the
sector and connecting them. The event intends to bring
organisations and investors together to share insights and
innovation to support R&D companies in their current and future
therapeutics and technology developments.
IXICO will share a pre-recorded presentation by Robin Wolz, SVP
Science & Innovation at IXICO plc, titled 'Biomarkers for CNS
clinical trials from imaging and actigraphy.' Two AI approaches to
measure biomarkers in CNS disorders will be presented; the first
approach is a method based on deep learning to segment brain volume
in Huntington's disease and the second novel approach is the sleep
assessment in Parkinson's disease from wrist-worn actigraphy. There
will be an opportunity to set up one-to-one tele-meetings with
potential customers and investors.
To find out and more and to register please visit:
http://www.onhelix.com/
The pre-recorded presentation will also be made available on the
Company's website shortly after the event:
https://ixico.com/investors/company-information/investor-videos/
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Walbrook PR Ltd Tel: 020 7933 8780 or IXICO@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303
/ /
Alice Woodings 07407 804 654
About IXICO ( www.IXICO.com )
IXICO is dedicated to delivering insights in neuroscience. Our
mission is to transform the progression of our biopharmaceutical
clients' neurological therapeutic pipelines through the application
of novel imaging and digital biomarkers.
IXICO's data analytics services are used by the global
biopharmaceutical industry to interpret data from brain scans and
digital biosensors to enable better trial design, site
qualification, patient selection and clinical outcomes. We provide
technology-enabled services across all phases of clinical
evaluation. Our integrated digital platform provides a scalable and
secure infrastructure for the capture and analysis of regulatory
compliant clinical data to enable clients to make rapid, better
informed decisions. IXICO is also collaborating with partners to
develop new analytical techniques and companion digital health
products targeted at improving patient outcomes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEAEXXEALEEAA
(END) Dow Jones Newswires
July 08, 2020 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024